[A23-41] Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130
Last updated 15.06.2023
Project no.:
A23-41
Commission:
Commission awarded on 03.05.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with previously untreated chronic lymphocytic leukaemia
Result of dossier assessment:
- Patients without genetic risk factors for whom therapy with FCR (= fludarabine + cyclophosphamide + rituximab) is not suitable: after addendum now hint of considerable added benefit
- All other patients in the therapeutic indication: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-130 | Zanubrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-06-15 A G-BA decision was published.